Study of VS-6766 + Adagrasib in KRAS G12C NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of VS-6766 in combination with agagrasib in
patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C
inhibitor and experienced progressive disease.